Related Experiment Video

Updated: Dec 13, 2025

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method

Published on: October 7, 2025

231

MicroRNAs and Their Targetomes in Tumor-Immune Communication

Sunglim Cho1, Jesse W Tai1, Li-Fan Lu1,2,3

  • 1Division of Biological Sciences, University of California, San Diego, La Jolla, CA 92093, USA.

Cancers
|July 30, 2020
PubMed

Insights

MicroRNAs (miRNAs) are key regulators in cancer development. This review explores how tumor-derived miRNAs influence anti-tumor immunity and discusses new methods for identifying miRNA targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Cancer development involves complex gene expression changes.
  • MicroRNAs (miRNAs) are critical regulators of tumorigenesis.
  • The immune system plays a significant role in cancer progression.

Purpose of the Study:

  • To discuss the role of miRNAs in mediating cancer and immune system crosstalk.
  • To review novel experimental approaches for miRNA target identification.
  • To enhance understanding of miRNA-mediated gene regulation in malignancies and genetic disorders.

Main Methods:

  • Literature review of miRNA function in cancer.
  • Analysis of miRNA's role in immune response modulation.
  • Overview of current experimental techniques for miRNA target discovery.

Main Results:

  • miRNAs act as central mediators between cancer and the immune system.
  • Aberrant miRNA expression can promote or inhibit tumorigenesis.
  • Tumor-derived miRNAs can impact tumor growth by regulating anti-tumor immunity.

Conclusions:

  • miRNAs are crucial in cancer-immune interactions.
  • Advanced miRNA target identification methods are vital for understanding gene regulation in diseases.
  • Further research into miRNA-mediated pathways can lead to novel therapeutic strategies.
Keywords:
immune regulationmiRNAoncomiRNApost-transcriptional regulation

More Related Videos

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.8K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.9K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.5K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.7K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.5K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K